ST. CHARLES, Mo: Eurofins Discovery, the leading provider of services and products to the drug discovery industry, announced a new collaboration with Amphilix AG, a Swiss-based biotech company, to support a program aimed at identifying a treatment modulating key disease mechanisms.

Amphilix AG will take advantage of Eurofins Discovery's DiscoveryOne offering, an integrated drug discovery platform providing expert support to progress programs to preclinical development and beyond.

Amphilix will engage Eurofins Discovery to prosecute the biology, pharmacology, ADME, and safety pharmacology aspects of the program, working in collaboration with the accomplished team at Eurofins Discovery to progress to a development candidate. The two organizations expect this to be the first of multiple programs in which they collaborate to discover new treatments for unmet medical needs.

Learn more about Eurofins Discovery and the DiscoveryOne integrated drug discovery solution at eurofinsdiscoveryservices.com.

Eurofins Discovery Announces Collaboration with Swiss Biotech Amphilix AG

Liked This Article? Be The First To Share it!

Class

Send